Incyte's Monjuvi Combo Reduces Blood Cancer Progression by 25%, Targets Expanded First-Line Use Despite High Side Effects
INCY sits 51% above its 52-week low of $63.925 on elevated volume (2.0× avg).
Summary
Incyte's Monjuvi combination therapy reduced disease progression or death risk by 25% in newly diagnosed diffuse large B-cell lymphoma patients, with a lower overall death rate despite higher severe side effects. This detailed data, presented at ASCO, supports Incyte's plan to seek expanded first-line approval for the combo, which could double the eligible patient population. This represents a significant commercial opportunity for Incyte. The company will pursue expanded approvals in the U.S. and Europe for this combo, which includes Bristol Myers Squibb's Revlimid.
At the time of this announcement, INCY was trading at $96.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.3B. The 52-week trading range was $63.93 to $112.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.